Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 31, 2017
Issued Date -
N/A
app pub date -
Nov 18, 2015
filing date -
Nov 4, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully